Catch pre-market movers with AI signals.
Countdown to BeOne Medicines Ltd. - Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Wall Street analysts expect BeOne Medicines Ltd.ONC-- - Sponsored ADR (ONC) to post quarterly earnings of $1.40 per share in its upcoming report, which indicates a year-over-year increase of 66.7%. Revenues are expected to be $1.66 billion, up 25.9% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors usually depend on consensus earnings and revenue estimates to assess the business performance for the quarter, delving into analysts' forecasts for certain key metrics often provides a more comprehensive understanding.
With that in mind, let's delve into the average projections of some BeOne MedicinesONC-- Ltd. - Sponsored ADR metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts forecast 'Revenues- Net product revenues' to reach $1.65 billion. The estimate points to a change of +26.4% from the year-ago quarter.
It is projected by analysts that the 'Revenues- Product Revenue- Other' will reach $18.45 million. The estimate suggests a change of -12.8% year over year.
The combined assessment of analysts suggests that 'Revenues- Product Revenue- BRUKINSA(Zanubrutinib)' will likely reach $1.27 billion. The estimate indicates a change of +33.4% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Product Revenue- XGEVA' will reach $69.33 million. The estimate indicates a year-over-year change of -14.7%.
Based on the collective assessment of analysts, 'Revenues- Net revenue from collaborations' should arrive at $10.28 million. The estimate points to a change of -22.3% from the year-ago quarter.
Analysts expect 'Revenues- Product Revenue- BLINCYTO' to come in at $29.76 million. The estimate points to a change of +16.3% from the year-ago quarter.
According to the collective judgment of analysts, 'Revenues- Product Revenue- KYPROLIS' should come in at $18.24 million. The estimate points to a change of -6.1% from the year-ago quarter.
The average prediction of analysts places 'Revenues- Product Revenue- POBEVCY' at $11.24 million. The estimate indicates a year-over-year change of 0%.
View all Key Company Metrics for BeOne Medicines Ltd. - Sponsored ADR here>>>BeOne Medicines Ltd. - Sponsored ADR shares have witnessed a change of +1.4% in the past month, in contrast to the Zacks S&P 500 composite's +1.7% move. With a Zacks Rank #3 (Hold), ONCONC-- is expected closely follow the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BeOne Medicines Ltd. - Sponsored ADR (ONC): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks is the leading investment research firm focusing on equities earnings estimates and stock analysis for the individual investor, including stock picks, stock screening, portfolio stock tracker and stock screeners. Copyright 2006-2026 Zacks Equity Research, Inc. editor@zacks.com (Manaing editor) webmaster@zacks.com (Webmaster)
